A low-cost antidepressant, fluvoxamine, may offer relief to individuals experiencing debilitating fatigue as a result of long COVID. A recent clinical trial demonstrated significant improvements in both fatigue levels and quality of life among participants who received the medication compared to those given a placebo.
A randomized clinical trial involving 399 adults investigated the effects of fluvoxamine on long COVID fatigue. The study revealed that fluvoxamine significantly reduced fatigue and improved patients’ overall quality of life, positioning it as one of the first medications to demonstrate meaningful benefits for this challenging condition.
The research offers a potential new avenue for treatment, addressing a key symptom impacting many individuals still struggling with health issues following an initial COVID-19 infection. The trial's findings suggest fluvoxamine could be a valuable tool in managing long COVID’s debilitating effects.
We don't rate truth. We strip the spin and show you which perspectives covered the story. You decide.
Read the original coverage
💬 Comments
📜 Comment Policy